title: Pharmacodynamic without pharmacokinetic interaction between cicloprolol, a partial beta 1-adrenoceptor agonist, and digoxin in healthy subjects.
abstract: 1. Cicloprolol is a partial beta 1-adrenoceptor agonist considered for the treatment of patients with coronary artery disease and impaired left ventricular function. In such patients, digoxin remains in widespread use. 2. We assessed the pharmacokinetic and pharmacodynamic interaction between oral cicloprolol 50 mg day-1 and oral digoxin 0.25 mg day-1 in 10 healthy male volunteers, using a double-blind, randomised protocol, during three 8 day periods. Digoxin was given alone during the first period to reach steady state; then digoxin was given with cicloprolol or placebo during the second and third periods, according to a cross-over design. 3. No significant adverse effects were observed. 4. The pharmacokinetics of digoxin were not different significantly at the end of the placebo-digoxin and cicloprolol-digoxin periods. 5. A significant increase in minimum heart rate and mean nocturnal heart rate, assessed by 24 h Holter recordings, was observed at the end of the cicloprolol-digoxin period as compared with the placebo-digoxin period (means +/- s.e. mean, 57.1 +/- 3.2 beats min-1 vs 52.2 +/- 3.1 beats min-1, P less than 0.01; and 65.6 +/- 3.8 beats min-1 vs 59.9 +/- 3.9 beats min-1, P less than 0.01, respectively). 6. A significant increase in left ventricular ejection fraction and shortening fraction, assessed by echocardiography, was noted at the end of the cicloprolol-digoxin period as compared with the placebo-digoxin period (means +/- s.e. mean, 66.4 +/- 1.4% vs 61.3 +/- 1.2%, P less than 0.05; and 37.0 +/- 1.1% vs 33.3 +/- 0.9%, P less than 0.05, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiovascular Diseases, René Descartes University, School of Medicine, Hôpital Cochin, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Weber
authors.forename: A
authors.initials: A
authors.lastname: Kahan
authors.forename: J L
authors.initials: JL
authors.lastname: Pinquier
authors.forename: J
authors.initials: J
authors.lastname: Julien
authors.forename: P
authors.initials: P
authors.lastname: Rosenzweig
authors.forename: G
authors.initials: G
authors.lastname: Bianchetti
authors.forename: P L
authors.initials: PL
authors.lastname: Morselli
authors.forename: O
authors.initials: O
authors.lastname: Dessault
authors.forename: D
authors.initials: D
authors.lastname: De Lauture
authors.forename: G
authors.initials: G
authors.lastname: Strauch
mesh_terms: D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D000328:Adult; D004077:Digoxin / Q000493:pharmacokinetics / Q000494:pharmacology*; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000493:pharmacokinetics / Q000494:pharmacology*; D011897:Random Allocation; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000318:Adrenergic beta-Agonists; D011412:Propanolamines; C053708:cicloprolol; D004077:Digoxin